Sean Wharton

15.4k total citations · 8 hit papers
94 papers, 8.3k citations indexed

About

Sean Wharton is a scholar working on Pharmacology, Endocrinology, Diabetes and Metabolism and Molecular Biology. According to data from OpenAlex, Sean Wharton has authored 94 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Pharmacology, 52 papers in Endocrinology, Diabetes and Metabolism and 29 papers in Molecular Biology. Recurrent topics in Sean Wharton's work include Pharmacology and Obesity Treatment (50 papers), Diabetes Treatment and Management (48 papers) and Metabolism, Diabetes, and Cancer (29 papers). Sean Wharton is often cited by papers focused on Pharmacology and Obesity Treatment (50 papers), Diabetes Treatment and Management (48 papers) and Metabolism, Diabetes, and Cancer (29 papers). Sean Wharton collaborates with scholars based in Canada, United States and Denmark. Sean Wharton's co-authors include John Wilding, Thomas A. Wadden, Barbara McGowan, Rachel L. Batterham, Ildiko Lingvay, Melanie J. Davies, Julio Rosenstock, Robert F. Kushner, Luc F. Van Gaal and Koutaro Yokote and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Sean Wharton

83 papers receiving 8.1k citations

Hit Papers

Once-Weekly Semaglutide in Adults with Overweight or O... 2018 2026 2020 2023 2021 2022 2018 2022 2022 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Once-Weekly Semaglutide in Adults with Overweight or Obesity
    2021 2.5k citations John Wilding, Rachel L. Batterham et al. New England Journal of Medicine profile →
  2. Tirzepatide Once Weekly for the Treatment of Obesity
    2022 1.8k citations Ania M. Jastreboff, Louis J. Aronne et al. New England Journal of Medicine profile →
  3. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
    2018 574 citations Sue D. Pedersen, Sean Wharton et al. profile →
  4. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
    2022 515 citations John Wilding, Rachel L. Batterham et al. Diabetes Obesity and Metabolism profile →
  5. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
    2022 469 citations W. Timothy Garvey, Rachel L. Batterham et al. Nature Medicine profile →
  6. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
    2023 259 citations Sean Wharton et al. New England Journal of Medicine profile →
  7. Tirzepatide for Obesity Treatment and Diabetes Prevention
    2024 133 citations Ania M. Jastreboff, Carel W. le Roux et al. New England Journal of Medicine profile →
  8. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
    2024 119 citations Henning Bliddal, Harold Bays et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sean Wharton Canada 28 4.8k 3.5k 2.6k 2.0k 1.8k 94 8.3k
David C.W. Lau Canada 33 2.9k 0.6× 2.5k 0.7× 2.4k 0.9× 1.2k 0.6× 1.0k 0.6× 98 6.7k
Vanita R. Aroda United States 49 7.3k 1.5× 1.4k 0.4× 1.6k 0.6× 2.1k 1.0× 3.2k 1.8× 166 10.2k
Christopher D. Still United States 43 1.7k 0.3× 1.2k 0.3× 2.5k 1.0× 2.7k 1.4× 1.2k 0.6× 162 6.9k
Ildiko Lingvay United States 52 11.2k 2.3× 4.6k 1.3× 3.3k 1.3× 3.8k 1.9× 5.2k 2.9× 220 15.6k
Juan P. Frías United States 48 8.3k 1.7× 3.1k 0.9× 2.4k 0.9× 2.8k 1.4× 3.9k 2.1× 172 11.4k
Alfredo Halpern Brazil 37 2.3k 0.5× 1.5k 0.4× 2.1k 0.8× 1.6k 0.8× 681 0.4× 138 5.6k
Bernhard Ludvik Austria 45 3.3k 0.7× 712 0.2× 2.9k 1.1× 3.0k 1.5× 2.0k 1.1× 177 8.7k
Leigh Perreault United States 40 3.0k 0.6× 774 0.2× 2.1k 0.8× 854 0.4× 1.7k 0.9× 102 6.4k
W. Timothy Garvey United States 33 3.1k 0.6× 694 0.2× 1.9k 0.7× 1.4k 0.7× 1.8k 1.0× 68 6.3k
Samuel Dagogo‐Jack United States 47 7.2k 1.5× 836 0.2× 2.0k 0.8× 2.6k 1.3× 2.4k 1.3× 201 11.2k

Countries citing papers authored by Sean Wharton

Since Specialization
Citations

This map shows the geographic impact of Sean Wharton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sean Wharton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sean Wharton more than expected).

Fields of papers citing papers by Sean Wharton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sean Wharton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sean Wharton. The network helps show where Sean Wharton may publish in the future.

Co-authorship network of co-authors of Sean Wharton

This figure shows the co-authorship network connecting the top 25 collaborators of Sean Wharton. A scholar is included among the top collaborators of Sean Wharton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sean Wharton. Sean Wharton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Roux, Carel W. le, Sean Wharton, Biykem Bozkurt, et al.. (2025). Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double‐blind, placebo‐controlled, phase 3 trial ( SYNCHRONIZE ™‐1). Diabetes Obesity and Metabolism. 28(1). 337–346.
2.
3.
Kuk, Jennifer L., et al.. (2025). Ethnic differences in weight loss during a clinical obesity management program. Clinical Obesity. 15(5). e70022–e70022.
4.
Wharton, Sean, Louis J. Aronne, Adam Stefański, et al.. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine. 393(18). 1796–1806. 10 indexed citations
5.
Bliddal, Henning, Harold Bays, Sébastien Czernichow, et al.. (2024). Semaglutide 2.4 mg efficacy and safety in people with obesity and knee osteoarthritis: Results: from the STEP 9 randomised clinical trial. Osteoarthritis and Cartilage. 32(6). 745–746. 14 indexed citations
6.
7.
Kuk, Jennifer L., et al.. (2024). Grazing and food addiction: Associations between varied patterns of overconsumption and addictive-like eating. Appetite. 204. 107768–107768. 3 indexed citations
8.
Aronne, Louis J., Naveed Sattar, Deborah B. Horn, et al.. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity (SURMOUNT-4). Diabetologie und Stoffwechsel. 19(S 01). S84–S85. 5 indexed citations
9.
Jastreboff, Ania M., Carel W. le Roux, Adam Stefański, et al.. (2024). Tirzepatide for Obesity Treatment and Diabetes Prevention. New England Journal of Medicine. 392(10). 958–971. 133 indexed citations breakdown →
10.
Ritz, Patrick, A. Sharma, Jakob B. Bjorner, et al.. (2023). Association entre une meilleure perte de poids et une meilleure amélioration de la fonction physique. Nutrition Clinique et Métabolisme. 37(2). e87–e87. 1 indexed citations
11.
Roux, Carel W. le, Emily R. Hankosky, Raleigh Malik, et al.. (2023). Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison. Diabetes Obesity and Metabolism. 25(9). 2626–2633. 25 indexed citations
12.
Nagpal, Taniya S., Sanjeev Sockalingam, Raed Hawa, et al.. (2023). A scoping review of obesity education interventions for current and prospective medical professionals in Canada. PubMed. 8. 100085–100085. 1 indexed citations
13.
Horn, Deborah B., Domenica Rubino, Rasmus Sørrig, et al.. (2023). A model‐based approach to predict individual weight loss with semaglutide in people with overweight or obesity. Diabetes Obesity and Metabolism. 25(11). 3171–3180. 18 indexed citations
14.
Amaro, Anastassia, Danny Sugimoto, & Sean Wharton. (2022). Efficacy and safety of semaglutide for weight management: evidence from the STEP program. Postgraduate Medicine. 134(sup1). 5–17. 42 indexed citations
15.
Garvey, W. Timothy, Rachel L. Batterham, Silvio Buscemi, et al.. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 28(10). 2083–2091. 469 indexed citations breakdown →
16.
Garvey, Timothy, Rachel L. Batterham, Silvio Buscemi, et al.. (2022). Wirkung von Semaglutid 2,4 mg vs. Placebo über 2 Jahre bei Erwachsenen mit Adipositas (STEP 5) (#7). 16(3). 168–169.
17.
Christensen, Rebecca, Sean Wharton, Jennifer D. Brooks, Susan J. Bondy, & Jennifer L. Kuk. (2021). The association of sex and calendar month with changes in weight: A retrospective cohort study of a community-based weight management clinic. Obesity Research & Clinical Practice. 15(5). 515–517. 1 indexed citations
18.
Wharton, Sean, et al.. (2019). Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post‐bariatric surgery. Clinical Obesity. 9(4). e12323–e12323. 102 indexed citations
19.
Wharton, Sean, et al.. (2019). The safety and effectiveness of commonly-marketed natural supplements for weight loss in populations with obesity: A critical review of the literature from 2006 to 2016. Critical Reviews in Food Science and Nutrition. 60(10). 1614–1630. 27 indexed citations
20.
Wharton, Sean, et al.. (2016). Predictors of early attrition and successful weight loss in patients attending an obesity management program. BMC Obesity. 3(1). 14–14. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David C.W. Lau Breakdown of academic impact, for papers by Vanita R. Aroda Breakdown of academic impact, for papers by Christopher D. Still Breakdown of academic impact, for papers by Ildiko Lingvay Breakdown of academic impact, for papers by Juan P. Frías Breakdown of academic impact, for papers by Alfredo Halpern Breakdown of academic impact, for papers by Bernhard Ludvik Breakdown of academic impact, for papers by Leigh Perreault Breakdown of academic impact, for papers by W. Timothy Garvey Breakdown of academic impact, for papers by Samuel Dagogo‐Jack
Rankless by CCL
2026